進階搜尋


 
系統識別號 U0026-0812200915231170
論文名稱(中文) 精神分裂症病患的情緒辨識與多巴胺第三接受體基因(DRD3) Ser9Gly 多型性之關聯
論文名稱(英文) Association of Emotion Perception with DRD3 Ser9Gly Polymorphisms in Schizophrenia Patients
校院名稱 成功大學
系所名稱(中) 行為醫學研究所
系所名稱(英) Institute of Behavioral Medicine
學年度 97
學期 2
出版年 98
研究生(中文) 徐筱媛
研究生(英文) Hsiao-Yuan Hsu
學號 S8695105
學位類別 碩士
語文別 英文
論文頁數 25頁
口試委員 指導教授-陸汝斌
召集委員-盧孟良
口試委員-林清華
指導教授-藍先元
中文關鍵字 情緒辨識  精神分裂症  多巴胺接受體  MSCEIT  社會認知 
英文關鍵字 MSCEIT  social cognition  schizophrenia  Dopamine receptors  emotion perception 
學科別分類
中文摘要 摘要
研究背景:
精神分裂症病患的情緒辨識是情緒認知能力之一,而情緒認知又在認知功能中扮演重要的角色。過去研究發現,精神分裂症患者在情緒辨識能力上有缺損,而多巴胺第三接受體被指出可能與情緒及社會相關行為有關。其中多巴胺第三接受體基因(Dopamine D3 receptor gene; DRD3)Ser9Gly更是精神分裂症候選基因之一。

研究目的:
本研究欲探討DRD3 Ser9Gly 基因多型性是否與精神分裂症患者之情緒辨識能力有關。

研究方法:
共收案118位精神分裂症住院病患。情緒辨識能力使用Mayer–Salovey–Caruso Emotional Intelligence Test (MSCEIT) Version 2.0 的A部分測量。經由抽血及PCR取得基因多型性資料。症狀嚴重度由Positive and Negative Syndrome Scale (PANSS)及Scale for the Assessment of Negative Symptoms (SANS)測量。另外所有病人都接受一般認知功能評估。

研究結果:
多元線性迴歸分析結果發現,在控制了年齡、性別、症狀嚴重度、抗精神病藥物類別及認知功能中的字詞延宕回憶後,Ser/Gly組之情緒辨識表現優於Ser/Ser組(p=0.036),而Gly/Gly組則與Ser/Ser組相較無異。

研究結論:
本研究發現DRD3 Ser9Gly 基因多型性在精神分裂症病患的情緒辨識能力中可能扮演重要角色,其中Ser/Gly表現最佳,而Gly/Gly表現最差,但Gly/Gly只有11 人,明顯少於其他2組,未來盼加大樣本數,以提高統計之效果量。

關鍵詞:多巴胺接受體、社會認知、MSCEIT、精神分裂症、情緒辨識
英文摘要 Abstract

Objective: Impaired social cognition, particularly emotion perception, is an essential feature of schizophrenia, but its molecular mechanism remains unclear. Previous study demonstrated that the dopamine D3 receptor was relevant to emotion activity and social behavior in rodent. Among the variances of D3 receptor gene (DRD3), the Ser9Gly polymorphism is associated with social function of patients with schizophrenia. This polymorphism may be also related with their emotion perception, a major domain of social cognitive functions.

Methods: To explore this potential molecular underpinning of social cognition, the DRD3 polymorphism is investigated in one hundred and eighteen chronic schizophrenia patients who had been stabilized with optimal antipsychotic treatment. The social cognition was evaluated by section A (facial emotion perception) of the Mayer–Salovey–Caruso Emotional Intelligence Test.

Results: The Ser/Gly group of patients was superior in emotion perception (p=0.036) while the potential contributing variables of age, gender, typical/atypical antipsychotics, positive and negative symptoms, and delayed recall memory were controlled for. The Ser9Gly polymorphism also tended to affect delayed verbal memory.

Conclusion: In conclusion, the DRD3 Ser/Gly variance may play an important role in facial emotion perception in patients with schizophrenia.


Key words: Dopamine receptors, social cognition, MSCEIT, schizophrenia, emotion perception
論文目次 CONTENTS
中文摘要 I
英文摘要 III
致謝 IV
CONTNETS V
LIST OF TABLES VI
CHAPTER 1 Introduction 1
CHAPTER 2 Methods 3
2.1 Participants 3
2.2 Clinical measures 4
2.3 Measurement of emotion perception 4
2.4 Neurocognition assessment 5
2.5 Genotyping 6
2.6 Statistical analysis 6
CHAPER 3 Results 8
3.1 Demographic data, clinical feature, and genotypes 8
3.2 DRD3 effect on emotion perception 8
3.3 DRD3 effect on verbal learning 9
CHAPTER 4 Discussion 10

REFERENCES 14
參考文獻 References

1. Green MF, Nuechterlein KH, Gold JM, et al. Approaching a Consensus Cognitive Battery for Clinical Trials in Schizophrenia: The NIMH-MATRICS Conference to Select Cognitive Domains and Test Criteria. Biol Psychiatry 2004;56:301-7.
2. Kee KS, Kern RS, Green MF, et al. Perception of emotion and neurocognitive functioning in schizophrenia: what’s the link? Psychiatry Res 1998a;81:57–65.
3. Kee KS, Horan WP, Salovey P, et al. Emotional intelligence in schizophrenia. Schizophr Res 2009;107:61-8.
4. Kohler CG, Walker JB, Martin EA, et al. Facial emotion perception in schizophrenia: A meta-analytic review. Schizophr Bull. In press.
5. Brothers L. The neural basis of primate social communication. Motiv Emot 1990;14:81-91.
6. Adolphs R.. The neurobiology of social cognition. Curr Opin Neurobiol 2001;11:231-9.
7. Kohler CG, Turner TH, Bilker WB, et al. Facial emotion recognition in schizophrenia: intensity effects and error pattern. Am J Psychiatry 2003;160:1768-74.
8. Schwartz JC, Diaz J, Pilon C, et al. Possible implications of the dopamine D(3) receptor in schizophrenia and in antipsychotic drug actions. Brain Res Rev 2000;31: 277-87.
9. Lane HY, Hsu SK, Liu YC, et al. Dopamine D3 receptor Ser9Gly polymorphism and risperidone response. J Clin Psychopharmacol 2005;25:6-11.
10. Sautel F, Griffon N, Sokoloff P, et al. Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents. J Pharmacol Exp Ther 1995;275:1239-46.
11. Kagaya T, Yonaga M, Furuya Y, et al. Dopamine D3 agonists disrupt social behavior in rats. Brain Res 1996;721:229-32.
12. Gendreau PL, Petitto JM, Schnauss R, et al. Effects of the putative dopamine D3 receptor antagonist PNU 99194A on motor behavior and emotional reactivity in C57BL/6J mice. Eur J Pharmacol 1997;337:147-55.
13. Lannfelt L, Sokoloff P, Martres MP, et al. Amino acid substitution in the dopamine D3 receptor as a useful polymorphism for investigating psychiatric disorders. Psychiatr Genet 1992;2:249-56.
14. Griffon N, Crocq MA, Pilon C, et al. Dopamine D3 receptor gene: organization, transcript variants, and polymorphism associated with schizophrenia. Am J Med Genet B Neuropsychiatr Genet 1996;67:63-70.
15. Lerer B, Segman RH, Fangerau H, et al. Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 2002;27:105-19.
16. Shaikh S, Collier DA, Sham PC, et al. Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia. Hum Genet 1996;97:714-9.
17. Scharfetter J, Chaudhry HR, Hornik K, et al. Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakastani patients. European Neuropsychopharmacology : Eur Neuropsychopharmacol 1999;10:17-20.
18. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. (SCID-I/P). Biometrics Research: New York State Psychiatric Institute; 2002.
19. First MB, Gibbon M, Spitzer RL, et al. Structured Clinical Interview for DSM-IV Axis II Personality Disorders, (SCID-II). Washington, D.C: American Psychiatric Press Inc.;1997.
20. Kay SR, Fiszbein A, Opler LA, The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76.
21. Harvey PO, Bodnar M, Sergerie K, et al. Relation between emotional face memory and social anhedonia in schizophrenia. J Psychiatry Neurosci 2009;34:102–10.
22. Hofer A, Benecke C, Edlinger M, et al. Facial emotion recognition and its relationship to symptomatic, subjective, and functional outcomes in outpatients with chronic schizophrenia. Eur Psychiatry 2009;24:27-32.
23. Mayer JD, Salovey P, Caruso DR, et al. Measuring emotional intelligence with the MSCEIT V2.0. Emotion 2003;3:97-105.
24. Reitan RM Validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Skills 1958;8:271-6.
25. Wechsler D. Wechsler Adult Intelligence Scale. 3rd ed. San Antonio (TX): Psychological Association; 1997.
26. Conners CK. Conners’ Continuous performance test (CPT II). Multi-Health Systems Inc; 2000.
27. Wechsler D. Wechsler Memory Scale. 3rd ed. San Antonio (TX): Psychological Association; 1997a.
28. Wechsler D. Wechsler Intelligence Scale for Child. 3rd ed. San Antonio (TX): Psychological Association; 1991.
29. Segman R, Neeman T, Heresco-Levy U, et al. Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry 1999;4:247-53.
30. Sergi MJ, Rassovsky Y, Widmark C, et al. Social cognition in schizophrenia: relationships with neurocognition and negative symptoms. Schizophr Res 2007;90:316-24.
31. Eack SM, Greeno CG, Pogue-Geile MF, et al. Assessing social-cognitive deficits in schizophrenia with the Mayer-Salovey-Caruso emotional intelligence test. Schizophr Bull. In press.
32. Staddon S, Arranz MJ, Mancama D, et al. Association between dopamine D3 receptor gene polymorphisms and schizophrenia in an isolate population. Schizophr Res 2005;73:49-54.
33. Xuan J, Zhao X, He G, et al. Effects of the dopamine D3 receptor (DRD3) gene polymorphisms on risperidone response: a pharmacogenetic study. Neuropsycopharmacology 2008;33:305-11.
34. Kohler CG, Bilker W, Hagendoorn M, et al. Emotion Recognition Deficit in Schizophrenia: Association with Symptomatology and Cognition Association with Symptomatology and Cognition. Biol Psychiatry 2000;48:127–36.
35. Crocq MA, Mant R, Asherson P, et al. Association between schizophrenia and homozygosity at the dopamine D3 receptor gene. Am J Med Genet B Neuropsychiatr Genet 1992;29:858-60.
36. McGuffin P, Owen M.J, Farmer AE. Genetic basis of schizophrenia. Lancet 1995;346:678-82.
37. Williams J, Spurlock G, Holmans P, et al. A meta-analysis and transmission disequilibrium study of association between the dopamine D3 receptor gene and schizophrenia. Mol Psychiatry 1998;3:141-9.
38. Mant R, Williams J, Asherson P, et al. 1994. Relationship between homozygosity at the dopamine D3 receptor gene and schizophrenia. Am J Med Genet 54:21-6.
39. Salgado-Pineda P, Delaveau P, Blin O, et al. Dopaminergic Contribution to the Regulation of Emotional Perception. Clin Neuropharmacol 2005;28:228–37.
40. Meyer-Lindenberg A, Miletich RS, Kohn PD, et al. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci 2002;5:267-71.
41. Jonsson E, Sedvall G., Brene S, et al. Dopamine-related genes and their relationships to monoamine metabolites in CSF. Biol Psychiatry 1996;40:1032-43.
42. Davidson RJ, Putnam KM., Larson CL. Dysfunction in the neural circuitry of emotion regulation- a possible prelude to violence. Science 2000;289:591-4.
43. Scholten MR, Aleman A, Montagne B, et al. Schizophrenia and processing of facial emotions: sex matters. Schizophr Res 2005;78:61-7.
44. Orgeta V, Phillips LH. Effects of age and emotional intensity on the recognition of facial emotion. Exp Aging Res 2008;34:63-79.
45. Moreno C, Borod JC, Welkowitz J, et al. The perception of facial emotion across the adult life span. Dev Neuropsychol 1993;9:305–14.
46. Wolwer W, Streit M, Polzer U, et al. Facial affect recognition in the course of schizophrenia. Eur Arch Psychiatry Clin Neurosci 1996;246:165-70.
47. Kee KS, Kern RS, Marshall BD, et al. Risperidone versus haloperidol for perception of emotion in treatment-resistant schizophrenia: preliminary findings. Schizophr Res 1998b;31:159–65.
48. Littrell KH, Petty RG, Hilligoss NM, et al. Improvement in social cognition in patients with schizophrenia associated with treatment with olanzapine. Schizoph Res 2003;66:201–2.
49. Harvey PD, Patterson TL, Potter LS, et al. Improvement in social competence with short-term atypical antipsychotic treatment: a randomized, double-blind comparison of quetiapine versus risperidone for social competence, social cognition, and neuropsychological functioning. Am J Psychiatry 2006;163:1918-25.
50. Herbener ES, Hill SK, Marvin RW, et al. Effects of antipsychotic treatment on emotion perception deficits in first-episode schizophrenia. Am J Psychiatry 2005;162:1746–48.
51. Krolak-Salmon P, Hnaff MA, Vighetto A, et al. Early amygdala reaction to fear spreading in occipital, temporal, and frontal cortex: a depth electrode ERP study in human. Neuron 2004;42:665-76.
52. Drabant EM, Hariri AR, Meyer-Lindenberg Andreas, et al. Catechol O-methyltransferase Val158Met Genotype and Neural Mechanisms Related to Affective Arousal and Regulation. Arch Gen Psychiatry 2006;63:1396-406.
53. Swant J, Stramiello M, Wagner JJ. Postsynaptic dopamine D3 receptor modulation of evoked IPSCs via GABA(A) receptor endocytosis in rat hippocampus. Hippocampus. 2008;18:492-502.
54. Szekeres G, Kri S, Juhsz A, et al. Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2004;124B:1-5.
55. Bombin I, Arango C, Mayoral M, et al. DRD3, but not COMT or DRD2, genotype affects executive functions in healthy and first-episode psychosis adolescents. Am J Med Genet B Neuropsychiatr Genet 2008;147B:873-9.
56. Lane HY, Liu Y., Huang CL, et al. Prefrontal executive function and D1, D3, 5-HT2A and 5-HT6 receptor gene variations in healthy adults. J Psychiatry Neurosci 2008;33:47-53.
57. Green MF, Olivier B, Crawley JN, et al. Social cognition in schizophrenia: recommendations from the MATRICS new approaches conference. Schizophr Bull 2005;31:882-7
論文全文使用權限
  • 同意授權校內瀏覽/列印電子全文服務,於2010-07-28起公開。
  • 同意授權校外瀏覽/列印電子全文服務,於2010-07-28起公開。


  • 如您有疑問,請聯絡圖書館
    聯絡電話:(06)2757575#65773
    聯絡E-mail:etds@email.ncku.edu.tw